Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
BIOD [NASD]
Biodel Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own10.21% Shs Outstand62.16M Perf Week-1.77%
Market Cap69.00M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float61.94M Perf Month-12.60%
Income-14.50M PEG- EPS next Q-0.11 Inst Own9.60% Short Float1.23% Perf Quarter-20.14%
Sales- P/S- EPS this Y46.80% Inst Trans-18.50% Short Ratio2.75 Perf Half Y-28.39%
Book/sh0.67 P/B1.66 EPS next Y19.30% ROA-64.20% Target Price5.00 Perf Year-46.38%
Cash/sh0.29 P/C3.88 EPS next 5Y- ROE-73.50% 52W Range0.99 - 2.51 Perf YTD-16.54%
Dividend- P/FCF- EPS past 5Y18.40% ROI- 52W High-55.78% Beta2.25
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low12.12% ATR0.07
Employees30 Current Ratio8.80 Sales Q/Q- Oper. Margin- RSI (14)43.26 Volatility4.09% 5.29%
OptionableYes Debt/Eq0.00 EPS Q/Q56.10% Profit Margin- Rel Volume0.24 Prev Close1.14
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume277.33K Price1.11
Recom1.80 SMA20-2.72% SMA50-6.12% SMA200-24.46% Volume67,638 Change-2.63%
May-18-15Initiated ROTH Capital Buy $5
May-10-13Upgrade Ladenburg Thalmann Neutral → Buy $6
Apr-16-12Upgrade JMP Securities Mkt Perform → Mkt Outperform $3
May-26-11Initiated Global Hunter Securities Accumulate $5
Feb-04-11Reiterated Wedbush Outperform $7 → $5
Dec-10-10Reiterated Wedbush Outperform $10 → $7
Nov-02-10Reiterated Wedbush Outperform $17 → $10
Nov-02-10Downgrade Ladenburg Thalmann Buy → Neutral $14 → $2
Oct-19-10Initiated JMP Securities Mkt Perform
Mar-25-09Reiterated Wedbush Morgan Buy $10 → $16
Mar-25-09Reiterated Ladenburg Thalmann Buy $9.50 → $14
Dec-11-08Reiterated Ladenburg Thalmann Buy $11 → $9.50
Nov-20-08Reiterated Cantor Fitzgerald Buy $33 → $15
Sep-19-08Downgrade Argus Buy → Sell
Sep-11-08Initiated Oppenheimer Perform
Sep-08-08Reiterated Ladenburg Thalmann Buy $23 → $11
May-16-08Initiated Cantor Fitzgerald Buy $33
May-02-08Initiated Pacific Growth Equities Buy
Feb-27-08Initiated JP Morgan Overweight
Feb-25-08Initiated Punk, Ziegel & Co Buy $23
May-21-15 04:02PM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
07:00AM  Biodel Announces Phase 2b Clinical Trial Initiation of BIOD-531, the Company's Concentrated, Ultra-Rapid-Acting, Prandial/Basal Combination Insulin Candidate Marketwired
May-19-15 01:04PM  BIODEL INC Financials
May-18-15 07:00AM  Biodel Appoints Ms. Arlene M. Morris to Its Board of Directors Marketwired
05:44AM  Coverage initiated on Biodel by ROTH Capital
May-09-15 08:09PM  10-Q for Biodel, Inc. at Company Spotlight
May-07-15 05:30PM  BIODEL INC Files SEC form 10-Q, Quarterly Report
May-06-15 04:46PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  Biodel Reports Second Quarter Fiscal Year 2015 Financial Results Marketwired
07:07AM  Q2 2015 Biodel Inc Earnings Release - 4:00 pm ET
May-01-15 09:48AM  Biodel to Report Second Quarter Fiscal Year 2015 Financial Results on May 6, 2015 Marketwired
01:02AM  Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior Usability Compared to Marketed Glucagon Kits in Human Factors Study at noodls
01:02AM  Biodel Announces Pricing of Public Offering of Common Stock at noodls
Apr-20-15 10:03AM  BIODEL INC Files SEC form 8-K, Other Events
Apr-16-15 06:03PM  Nasdaq stocks posting largest volume increases
Apr-15-15 10:42AM  BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agree +10.68%
08:00AM  Biodel Announces Pricing of Public Offering of Common Stock Marketwired
Apr-06-15 08:17AM  BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior Usability Compared to Marketed Glucagon Kits in Human Factors Study Marketwired
Apr-01-15 12:15AM  Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial at noodls
12:15AM  Biodel to Present at the 27th Annual ROTH Conference at noodls
Mar-18-15 01:30PM  BIODEL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Mar-16-15 08:41AM  BIODEL INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
07:00AM  Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial Marketwired
Mar-04-15 08:00AM  Biodel to Present at the 27th Annual ROTH Conference Marketwired
Mar-01-15 01:56AM  Biodel Reports First Quarter Fiscal Year 2015 Financial Results at noodls
Feb-14-15 07:07PM  10-Q for Biodel, Inc. at Company Spotlight
Feb-12-15 05:01PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
05:00PM  BIODEL INC Files SEC form 10-Q, Quarterly Report
04:06PM  Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
04:00PM  Biodel Reports First Quarter Fiscal Year 2015 Financial Results Marketwired
07:07AM  Q1 2015 Biodel Inc Earnings Release - 4:00 pm ET CCBN
Feb-09-15 05:58PM  UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog Zacks
Feb-06-15 09:32AM  McKesson Beats on Earnings & Revenues in Q3, Ups View - Analyst Blog Zacks
09:00AM  On MannKind, Diabetics Have One Up On Wall Street at Forbes
Feb-05-15 06:27PM  Roche Reports Positive Data on Leukemia Drug Gazyva - Analyst Blog Zacks
03:31PM  BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog Zacks
08:00AM  Biodel to Report First Quarter Fiscal Year 2015 Financial Results on February 12, 2015 Marketwired
Feb-04-15 06:46PM  Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog Zacks
06:07PM  Novartis' Alcon Receives FDA Approval for Pazeo Solution - Analyst Blog Zacks
09:21AM  Salix Pharmaceuticals (SLXP) in Focus: Stock Jumps 5.1% - Tale of the Tape Zacks
Feb-03-15 03:45PM  Will McKesson (MCK) Disappoint Q3 Earnings Estimates? - Analyst Blog Zacks
11:03AM  Mallinckrodt Beats on Q1 Earnings, Sales Miss Estimates - Analyst Blog Zacks
Feb-02-15 05:50PM  Will Mallinckrodt (MNK) Disappoint Q1 Earnings Estimates? - Analyst Blog Zacks
03:45PM  Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog Zacks
03:20PM  Will Allergan (AGN) Disappoint on Earnings This Quarter? - Analyst Blog Zacks
Jan-30-15 05:55PM  Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog Zacks
Jan-29-15 05:30PM  Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog Zacks
04:30PM  Will Generics Continue to Hit Eli Lilly's (LLY) Q4 Earnings? - Analyst Blog Zacks
Jan-28-15 06:30PM  Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog Zacks
Jan-27-15 05:38PM  NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog Zacks
05:15PM  Will AmerisourceBergen (ABC) Earnings Surprise in Q1? - Analyst Blog Zacks
Jan-26-15 05:20PM  Shire's Elvanse Gets Positive Response for ADHD in Adults - Analyst Blog Zacks +5.48%
Jan-23-15 05:50PM  Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? - Analyst Blog Zacks +5.80%
Jan-22-15 07:00PM  UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Zacks
Jan-21-15 05:35PM  Valeant's Bausch + Lomb Imaging System Cleared by FDA - Analyst Blog Zacks
04:15PM  CytRx Relieved as FDA Lifts Partial Hold on Oncology Drug - Analyst Blog Zacks
04:05PM  Immunomedics Reports Data on Oncology Candidate - Analyst Blog Zacks
02:00PM  ARIAD's Iclusig Endorsed by EC for All Approved Indications - Analyst Blog Zacks
Jan-20-15 02:10PM  Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst Blog Zacks
Jan-19-15 02:10PM  UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog Zacks
Jan-15-15 04:30PM  Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Zacks
02:30PM  Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog Zacks
Jan-07-15 05:49PM  Wednesday's After-Hours Movers Benzinga
04:23PM  BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:00PM  Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins in Patients With Diabetes Who Require High Doses of Insulin Marketwired
Dec-21-14 07:07PM  10-K for Biodel, Inc. Company Spotlight
Dec-19-14 04:03PM  BIODEL INC Files SEC form 10-K, Annual Report EDGAR Online
Dec-17-14 04:31PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
04:00PM  Biodel Reports Fourth Quarter Fiscal Year 2014 Financial Results Marketwired
07:07AM  Q4 2014 Biodel Inc Earnings Release - 4:00 pm ET CCBN
Dec-10-14 04:20PM  Roche (RHHBY) Presents Positive Data on Haemophilia Drug Zacks
04:00PM  Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014 Marketwired
Dec-09-14 07:00AM  Cempra (CEMP) in Focus: Stock Rises 11.4% in Session Zacks
05:52AM  Tetraphase Pharmaceuticals (TTPH) Jumps: Stock Up 8.8% Zacks
Dec-04-14 04:19PM  Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program Marketwired -5.41%
Nov-18-14 04:02PM  Biodel Successfully Defends Ultra-Rapid-Acting Insulin Formulation Technology in European Patent Office Opposition Proceedings Marketwired
06:17AM  ArQule (ARQL) Shows Strength: Stock Adds 6 % in Session Zacks
06:13AM  Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% Zacks
Nov-07-14 05:46AM  Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% Zacks
Nov-03-14 05:47AM  Flamel Technologies (FLML) Crumbles: Stock Falls by 7.1% Zacks
Oct-30-14 07:24AM  Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% Zacks
Oct-27-14 09:37AM  BIODEL INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Sep-15-14 07:00AM  Biodel Announces Data Presentations at the 50th Annual Meeting of the EASD Marketwired
Aug-27-14 04:00PM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Aug-25-14 04:00PM  Biodel Appoints Gary G. Gemignani as Chief Financial Officer Marketwired
Aug-14-14 09:58AM  Biodel Q3 Loss Narrower than Expected, Gives Pipeline Update Zacks
Aug-13-14 05:01PM  BIODEL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-11-14 05:02PM  [video] Stocks Close Higher, But Off Day's Highs at TheStreet
04:30PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
04:05PM  Biodel Reports Third Quarter Fiscal Year 2014 Financial Results Marketwired
07:30AM  Biodel's insulin drug found effective in trial Reuters
07:07AM  Q3 2014 BIODEL INC Earnings Release - 4:00 pm ET CCBN
07:00AM  Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized Meals Compared to Marketed Insulins in a Phase 2 Clinical Trial in Patients With Type 2 Diabetes Marketwired
Aug-06-14 07:00AM  Biodel to Present at the Wedbush PacGrow Life Sciences Management Access Conference Marketwired
Aug-05-14 07:00AM  Biodel to Report Third Quarter Fiscal Year 2014 Financial Results on August 11, 2014 Marketwired
Jul-28-14 06:00AM  Biodel Enters Into $15 Million Equity Commitment With Lincoln Park Capital Marketwired
Jun-11-14 07:30AM  Biodel to Present at the JMP Securities Healthcare Conference Marketwired
Jun-10-14 07:00AM  Biodel to Present Data on Ultra-Rapid-Acting Insulin and Glucagon Product Candidates at 2014 American Diabetes Association Scientific Sessions Marketwired +5.41%
May-23-14 04:02PM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.